Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06017037
Other study ID # REPAC01
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 19, 2023
Est. completion date May 1, 2024

Study information

Verified date May 2023
Source University of Oxford
Contact Alexander Smith, MBBS
Phone 07865 618318
Email alexander.smith@psych.ox.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this experimental medicine study is to examine the effect of increasing serotonin on reward processing in healthy volunteers. The main questions it aims to answer are: 1. Does a subacute increase in serotonin influence the activation regions during reward learning 2. Does a subacute increase in serotonin influence behavioural markers of reward valuation (effort task), responsiveness (taste task) and learning (learning task) Participants will be: given a 7-day course of the selective serotonin reuptake inhibitor, citalopram. undergo behavioural testing complete a reward learning task whilst undergoing fMRI Researchers will compare results against a placebo group.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the research - Aged between 18 to 65 years - Sufficient knowledge of English language to understand and complete study tasks Exclusion Criteria: - Current or past probable diagnosis of psychiatric illness, according to DSM-5 criteria, requiring intervention by a healthcare professional, including but not limited to psychosis, bipolar disorder, major depression, OCD, PTSD, substance abuse disorder or any eating disorder - Current or past diagnosis of any significant personality disorder (e.g. borderline personality disorder) according to self-report - Diagnosis of attention deficit hyperactive disorder or autistic spectrum disorder that impairs daily functioning, requires pharmacotherapy or in the opinion of the study medic would affect the scientific integrity of the study - Current use of medication that might interact with the effects of citalopram or affect the scientific integrity of the study - Previous suicide attempt or previous prolonged period (e.g. > 5 days) of thoughts to end life - Known contraindication to citalopram including: past allergic reaction to citalopram or any other medicines, diagnosis of a cardiovascular condition, glaucoma, type 1 or type 2 diabetes, diagnosis of epilepsy, previous diagnosis of angle-closure glaucoma, or current use of any other medication whose use interacts with citalopram (according to BNF guidance) e.g. associated with prolonged QT-interval - Any other current or past medical conditions which in the opinion of the study medic may interfere with the safety of the participant or the scientific integrity of the study including epilepsy/seizures, brain injury, hepatic or renal disease, diabetes, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions - First-degree relative with a diagnosis of schizophrenia-spectrum or other psychotic disorder, or bipolar disorder - Severely underweight (BMI<17) or very obese (BMI>40) in a manner that renders them unsuitable for the study in the opinion of the study medic - Heavy use of cigarettes (smoke > 20 cigarettes per day) - Heavy use of caffeine (drink > 4 250ml cups/cans of coffee/energy drinks per day) - Lactose intolerance (due to the study involving administration of a lactose placebo tablet) - Known allergy to citric acid, sodium chloride, sucrose or quinine - Pregnancy (as determined by urine pregnancy test taken during the Part 2 screening visit), breast feeding or plans to become pregnant - past history of dependence on illicit substances or regular illicit substance use within previous three months - Evidence of current or past harmful use of alcohol - previous participation in a study involving the tasks used in this study or involving use of citalopram in the last year - physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging - ongoing deficit in sense of smell or taste e.g. following Covid-19 infection - Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator - Not suitable for MRI neuroimaging e.g. claustrophobia, difficulty remaining still for duration of scan - Any MRI contraindications outlined in FMRIB 3 Tesla scanning safety form

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Citalopram 20mg
Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
Placebo
Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days

Locations

Country Name City State
United Kingdom Neurosciences building, Department of Psychiatry, Warneford hospital Oxford Oxfordshire

Sponsors (1)

Lead Sponsor Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reward & aversive learning: behavioural correlates Optimal choice learning rate of conditioned stimuli to win and loss outcomes.
During an instrumental reinforcement learning task participant will complete trials with a pair of symbols (the valence will either be loss or win, which is implicit).
One symbol will be high chance of that outcome (either win or loss depending on the valence of the pair) and the other low chance of the outcome.
In the win pair the optimal choice is the high chance symbol (i.e. to win), in the loss pair the optimal choice is the low chance option (i.e. avoid loss).
In each allocation group the proportion of participants making an optimal choice will be calculated on a trial-by-trial basis. This provide the learning rate outcome.
Day 7-9 of treatment
Primary Reward & aversive learning: neural correlates Activity of a network of brain regions associated with reward learning (during anticipation and outcome), in response to a positive & negative outcomes in reward learning task.
This will be the difference in BOLD activation in certain brain regions (pertinent to reward processing) between allocation groups during the anticipation stage and the outcome stage of the instrumental learning task.
Day 7-9 of treatment
Secondary Resting state Resting state fMRI activation Day 7-9 of treatment
Secondary Subjective rating of primary reward Subjective rating of four tastes (sweet, salt, sour & bitter) in terms of intensity, anticipation of pleasurableness and actual pleasurableness. Day 0 and day 7-9 of treatment
Secondary Reward & aversive learning: behavioural volatile reward learning task: total money won Amount of money won/lost & total amount of money received. day 7-9 of treatment
Secondary Motivational reward task Participants are asked to accept or decline hypothetical offers made of various combinations of reward and physical effort (grip strength). For a limited number of offers participants are asked to actually expend effort for offers too. The investigators will examine
Proportion of offer acceptance for various levels of reward and effort
proportion of accepted offers successfully obtained
day 7-9 of treatment
Secondary Reward & aversive learning: behavioural volatile reward learning task: learning rate Learning rate of optimal choices changes during the task. Proportion of participants in each allocation arm making an optimal choice on a trial-by-trial basis will provide the learning rate for each group.
Provides sensitive measure of reward and aversive learning rates.
day 7-9 of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Enrolling by invitation NCT06035562 - Promoting Positive Emotional Functioning in Police and Military Populations N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Withdrawn NCT05507385 - Imagine a Brighter Future: An Intervention to Improve Positive Emotions in Young People N/A
Completed NCT05383248 - Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients N/A
Suspended NCT03715400 - Mobile Virtual Positive Experiences for Anhedonia N/A
Recruiting NCT05240352 - Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression N/A
Recruiting NCT03915613 - Brain Insulin Resistance in Mood Disorders Phase 1/Phase 2
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Completed NCT03939676 - Evaluating Motivation and Reward Mechanisms and Brain Substrates in Adults With Obesity
Enrolling by invitation NCT06285474 - Investigating LIFUP in Anhedonic Depression N/A
Recruiting NCT05870501 - Synaptic Imaging and Network Activity in Treatment Resistant Depression N/A
Active, not recruiting NCT03848715 - Sleep and Healthy Aging Research on Depression for Younger Women Phase 1
Completed NCT05165394 - Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD Phase 2
Completed NCT04647019 - The Effects of Wild Blueberries on Depressive Symptoms in Young Adults N/A
Recruiting NCT06075771 - Dopaminergic Therapy for Anhedonia - 2 Phase 4
Completed NCT02958228 - The Effect of Computerized Cognitive Training on Mood and Thinking Style Amongst Patients in Inpatient Settings N/A
Recruiting NCT05991713 - Geolocation Positional System (GPS) Experience N/A
Completed NCT05084924 - Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia N/A